MedTrace Logo

TAP-patients With Robotic Assisted Lap Prostatectomy

NCT01582477 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-06-14

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to assess the safety and efficacy of EXPAREL when administered via infiltration into the transversus abdominis plane (TAP) to prolonged postsurgical analgesia in men undergoing robot-assisted laparoscopic prostatectomy.

Conditions

  • Postsurgical Pain
  • Analgesia
  • Prostatectomy

Interventions

DRUG

EXPAREL 20 mL

EXPAREL 266 mg (undiluted)

DRUG

EXPAREL 40 mL

EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.

Sponsors & Collaborators

  • Pacira Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Andrew Sternlicht, MD · Steward St. Elizabeth's

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-05-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01582477 on ClinicalTrials.gov